ArticleChinese medicine2025
Biomimetic nanodelivery system with simultaneous blood-brain barrier-crossing and neuroprotective abilities for anti-parkinsonian therapy.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics.Bioactive materials · 2026Review
- Nanotechnology for efficient delivery of TCM active ingredients in treating brain diseases.Materials today. Bio · 2026Review
- Overcoming Oxidative Stress in Parkinson's Disease: NADPH Oxidase 4 (NOX4) as a Potential Therapeutic Target.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundParkinson's disease (PD) has emerged as a critical public health challenge amidst global population aging. The pathogenesis of PD is extremely complex. Notably, evidence showed that neuroinflammation due to microglial activation is a critical driver of dopaminergic neuron loss in patients with PD. Therefore, several strategies aimed at alleviating neuroinflammation are currently being tested for the treatment of PD. However, current anti-inflammatory agents exhibit limited therapeutic efficacy in vivo due to hindrances caused by the blood-brain barrier (BBB). To overcome BBB-related challenges, we developed a biomimetic nanodelivery system (DCM@Nar-NCs) by encapsulating naringenin nanocrystals (Nar-NCs) within differentiated HL-60 cell membranes. Our analysis demonstrated that DCM@Nar-NCs could act as an innovative nanoplatform for PD therapy, showing BBB penetration capabilities and exhibiting precise accumulation at sites of neuroinflammation. This targeted delivery enables more precise and potent treatment than existing therapeutic modalities.
methodsThe BBB penetration efficiency and brain-targeted delivery of DCM@Nar-NCs were assessed both in vitro and in vivo. The neuroprotective effects were comprehensively investigated in cellular and animal levels. Finally, the ability of DCM@Nar-NCs to ameliorate motor dysfunction and cognitive impairment was validated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse models.
resultsDCM@Nar-NCs exhibited significantly enhanced BBB permeability and could exert dual therapeutic effects. Notably, DCM@Nar-NCs modulated microglial polarization (pro-inflammatory M1 phenotype to neuroprotective M2 phenotype), thereby attenuating neuroinflammatory cascades. Additionally, DCM@Nar-NCs could ameliorate mitochondrial dysfunction and thereby prevent the apoptosis and destruction of dopaminergic neurons. Finally, behavioral assessments in animal models confirmed the remarkable capacity of DCM@Nar-NCs to reverse PD-related motor deficits and cognitive impairment.
conclusionCollectively, the novel PD treatment approach developed in this study offers superior biosafety and treatment efficacy, highlighting its strong potential for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.